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Protonpump inhibitors have become ofpivotal importancefor the treatment ofGERD. Thepurpose
ofthis paper is to review the interaction between Helicobacter pylori and PPIs in the treatment of
GERD. H. pylon exaggerates the acid suppressive effects of PPIs. During treatment with these
drugs, H. pylonr-positive subjects thus have a higher intragastric pH than H. pylori-negative sub-
jects. The mechanismfor thisphenomenon remains to be elucidated. We hypothesize that it is relat-
ed to H. pylon-induced corpus gastritis, which impairs parietal cellfunction. The available evi-
dence suggests that thisphenomenon has no clinical relevancefor the treatment ofGERD. The 24-
hr esophagealpHduring PPI treatment does notdepend on the H. pylon status, nor does the med-
ication dose neededfor maintenance therapy or the number ofclinical relapses during such thera-
py depend on the H. pylon status. PPIs, on the other hand, also affect H. pylori. During treatment
with these drugs, thepattern ofbacterial colonization andassociatedgastritis shiftsproximally. The
increasedgastritis ofthe body mucosa is associated with a more rapiddevelopmentofatrophic gas-
tritis, a condition characterizedby a loss ofgastric glands andassociated with an increased cancer
risk. For these reasons, one has to consider H. pylon eradication in infected GERDpatients in need
ofPPI maintenance therapy.
INTRODUCTION
Proton pump inhibitors (ppIS)b are
very effective for the initial and mainte-
nance treatment of gastroesophageal
reflux disease. Recent evidence suggests
that Helicobacter pylori infection may
interact with this treatment, both with
respect to efficacy as well as with respect
to long term side effects. The purpose of
this paper is to review the effect of H.
pylori on PPIs, as well as the effect ofPPIs
on H. pylori based on the present literature
data.
EFFECTS OF H. pyloriON PROTON
PUMP INHIBITORS
PPIs, H. pylori andgastric pH
In 1995, Verdui and colleagues from
Switzerland showed that intragastric pH
during omeprazole therapy depends on the
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H. pylori status of an individual [1]. They
measured the 24-hr intragastric pH in 14
H. pylori-negative and 18 H. pylori-posi-
tive healthy volunteers both during treat-
ment with 20 mg omeprazole and during
treatment with placebo. During treatment
with placebo, median 24-hr pH values did
not differ between H. pylori-infected and -
uninfected subjects (1.5 vs. 1.4). However,
during treatment with omeprazole, median
24-hr pH values were higher in H. pylori-
positive than in H. pylori-negative sub-
jects (5.5 vs. 4.0). These results were sub-
sequently confirmed in anumber ofdiffer-
ent studies. The same group showed that
H. pylori eradication resulted in a
decrease of24 hour intragastric pH during
omeprazole therapy, whereas the pH dur-
ing the untreated state did not change [2].
Anotherpaper showed thatthe same effect
also occurred in duodenal ulcer patients
[3]. These measurements were performed
six to eight weeks after H. pylori eradica-
tion. The efficacy ofomeprazole in lower-
ing intragastric pH remains permanently
decreased after H. pylori eradication, as
shown by repeated measurements one
year after bacterial eradication [4]. The
effect of H. pylori on drug-induced intra-
gastric acid reduction is not restricted to
omeprazole or proton pump inhibitors
alone. In another recent study, 18 H.
pylori-infected duodenal ulcer patients
were treated with 300 mg ranitidine daily
before and six to eight weeks after bacter-
ial eradication. Before eradication, the
intragastric pH during ranitidine treatment
was higher than after eradication [5]. In
summary, H. pylori infection exaggerates
the effect of acid suppressing drugs on
intragastric pH.
The mechanism underlying this phe-
nomenon remains to be elucidated.
Possible explanations include the hypoth-
esis that it is due to bacterial production of
ammonia buffering gastric acid, or to a
direct effect ofbacterial products, such as
the vacuolating cytotoxin A and the acid
inhibitory protein ofH. pylori, on parietal
cell function. In our opinion, the most
likely explanation is that it is related to the
effect of acid suppression on the distribu-
tion ofH. pylori gastritis. H. pyloriprefers
an acidophilic environment. The distribu-
tion of bacterial colonization and that of
associated gastritis depend on acid secre-
tion. Profound acid suppressive therapy
changes the usual antral predominant gas-
tritis pattern into a corpus predominant
pattern [6]. Inflammation of the corpus
mucosa impairs acid production. As such,
the increase of corpus gastritis will exag-
gerate the acid-lowering effect of acid
suppressive therapy.
The magnitude of this phenomenon
increases with more profound acid sup-
pression. In case oftreatment with 300 mg
ranitidine daily, H. pylori eradication led
to a decrease ofthe percentage oftime per
24 hours during which the intragastric pH
was greater than 4.0 from 39 to 27 percent
[5]. In contrast, this percentage changed
from 73 to 38 during treatmentwith 20 mg
omeprazole daily [4]. This difference
between mild and profound acid suppres-
sion can be explained by the fact that more
pronounced acid suppression leads to
more severe corpus gastritis in H. pylori-
infected subjects. An additional explana-
tion could be that the effect ofH.pylori on
proton excretion is independent of acid
suppression, but small, and, therefore,
only measurable at higher pH due to its
log scale.
PPIs, H. pylori, and esophageal pH
Does the effect of H. pylori infection
on the efficacy of acid suppressive drugs
have any clinical relevance for the man-
agement of GERD? One could hypothe-
size that H. pylori-infected GERD
patients require a lower dose of acid sup-
pression than uninfected GERD patients.
A meta-analysis of three clinical trials
focused on disease relapse in 340 GERD
patients during 12 months treatment with
either ranitidine 300 mg, omeprazole 10Kuipers et al.: H. pylori, PPIs, and GERD 213
mg, or omeprazole 20 mg daily. In each
treatment group, the relapse rate was
somewhat higher among H. pylori-nega-
tive patients, but these differences were
not significant (Carlsson, R., Astra
Pharmaceuticals, Sweden, personal com-
munication). We followed 137 GERD
patients for 58 ± 15 months during treat-
ment with omeprazole [7]. Each patient
was studied by endoscopy before the start
of treatment and at annual follow-up.
Omeprazole was started at a dose of 20
mg daily. This dose was increased during
follow-up in case of endoscopic or symp-
tomatic relapse with steps of20 mg. Ifthe
required daily dose surpassed 40 mg, the
dosing scheme was adjusted to twice
daily. Although the H. pylori-negative
patients at baseline had more symptoms of
severe GERD, in particular Barrett's
esophagus, there was no difference at all
for the dose ofomeprazole needed in both
groups. The median daily dose in both
groups at the end offollow-up was 40 mg
(p = .35) [7]. Another very large interna-
tional study also focused on the efficacy of
maintenance treatment with omeprazole
forGERD. This study also did not observe
any association between H. pylori status
and the relapse rate or required omepra-
zole dose during 1496 patient years fol-
low-up [8]. Finally, in another study, we
measured 24-hr esophageal acid exposure
in 30 H. pylori-negative and 28 H. pylori-
positive patients with a Barrett's esopha-
gus at baseline and during treatment with
either 150 mg ranitidine twice daily or 40
mg omeprazole twice daily [9]. It
appeared that H. pylori infection did not
influence esophageal acid reflux in these
patients, nor did it influence the effect of
low or profound acid suppression on
reflux. Although none of these studies
used patients as their own controls by
studying them before and after H. pylori
eradication, they strongly suggest that H.
pylori status does not affect the efficacy of
acid suppressive therapy in the manage-
ment of GERD. This means that the dose
of acid suppression does not have to be
titrated upon H. pylori status.
EFFECTS OF PROTON PUMP
INHIBITORS ON H. pylori
PPIs and accelerated development of
atrophic gastritis
H. pylori exaggerates the effect of
proton pump inhibitors on intragastric pH.
On the other hand, proton pump inhibitors
also have a significant effect on H. pylori.
H. pylori is an acidophil with an optimum
pH, which, in the presence of urea, pre-
sumably lies around 5.0. Drugs that affect
acid production thus affect the intragastric
distribution ofH. pylori and thereby affect
H. pylori-associated gastritis. Acid sup-
pression induces an increased inflamma-
tion of the gastric body mucosa in H.
pylori-infected subjects [6, 10]. This effect
occurs at the start of therapy and persists
throughout the duration of therapy [11].
The magnitude of the effect depends on
the level of acid suppression. It has been
observed to a limited extent during H2-
blocker therapy [12] and is more pro-
nounced during intake ofPPIs [6, 10]. It is
associated with increased epithelial cell
proliferation [13].
We questioned whether the increased
severity ofcorpus gastritis induced by acid
suppressive therapy in H. pylori-infected
patients has any clinical relevance, in par-
ticular with respect to the development of
atrophic gastritis [6, 14]. The latter condi-
tion, characterized by a loss of gastric
glands [15], can develop as a result of
chronic active gastritis and is associated
with an increased gastric cancer risk.
Development ofatrophic gastritis is usual-
ly a slow process. It takes approximately
20 years before one out ofevery three sub-
jects with chronic gastritis has developed
signs of atrophic gastritis; the annual inci-
dence of atrophic gastritis among H.
pylori-infected subjects varied between 1214 Kuipers etal.: H. pylori, PPIs, and GERD
and 3 percent in a number of cohort stud-
ies [16-18]. These studies all focused on
"healthy" volunteers, i.e., subjects with a
presumable nonnal acid production. In
contrast, various cohort studies focusing
on patients with a condition that impaired
acid production, reported a 3.8 to 8.7 per-
cent annual incidence of atrophic gastritis
[14]. These studies focused on patients
with gastric ulcer disease [19], duodenal
ulcer patients after vagotomy [20, 21], or
on patients treated with omeprazole for
different indications [22, 23]. Although
none of these studies specified results
according to H. pylori status, the results
were rather concordant and contrasted
with the 1 to 3 percent annual incidence of
atrophic gastritis in cohorts of subjects
without specific disease or treatment.
Nevertheless, there were no direct compar-
isons of different populations within one
study available. It was also unknown
whether development of atrophic gastritis
in subjects with reduced acid output was
also associated with H. pylori, or with
other unidentified factors. For these rea-
sons, we prospectively compared two pop-
ulations of GERD patients [11]. One
group of 105 Dutch patients was treated
with omeprazole maintenance therapy and
another group of 72 Swedish patients was
treated with a fundoplication procedure,
without any further acid suppression. Both
groups were followed for five years with
endoscopy and gastric biopsy sampling at
regular intervals. All these specimens were
evaluated by one pathologist. Develop-
ment of atrophic gastritis was rare in the
H. pylori negative patients of both treat-
ment groups. Among the H. pylori-posi-
tive patients treated with a fundoplication,
the upper limit of the 95 percent confi-
dence interval for incidence of atrophic
gastritis was 2.2 percent, which is fully in
accordance with the findings of previous
studies in patients with unsuppressed acid
production [17]. In the H. pylori-positive
group treated with omeprazole however,
the annual incidence of atrophic gastritis
was 6.1 percent (95 percent CI 3.8-8.8)
[11]. After five years oftreatment, atrophy
was thus observed in approximately one
out of every three H. pylori-infected
patients treated with omeprazole, which is
in sharp contrast with the usual 20 years
needed for such a prevalence ofatrophy to
develop. Development of argyrophil cell
hyperplasia was also strongly associated
with H. pylori and atrophic gastritis [11].
Both atrophic gastritis and argyrophil cell
hyperplasia almost remained absent in the
group of non-infected patients. Based on
these findings and with the above-men-
tioned background, we concluded thatpro-
found acid suppressive therapy accelerates
the natural course of H. pylori gastritis
[11].
PPIs, H. pylori and the definition of
atrophic gastritis
The main arguments against our pub-
lication [11] in particular focused on the
definition of gastric atrophy, and the dif-
ference in mean age and country oforigin
ofthe two cohorts in our study. We defined
atrophic gastritis according to the interna-
tionally accepted up-dated Sydney classi-
fication as a condition with a loss of gas-
tric glands [15]. It has been suggested that
this condition does not exist without con-
comitant intestinal metaplasia. However,
glands that are lost are not necessarily
replaced with intestinal tissue. Atrophy
can occur without intestinal metaplasia, a
condition that, for instance, is commonly
observed in patients with pernicious ane-
mia [15]. The opposite, intestinal metapla-
sia without atrophy, may also occur.
Metaplastic cells can sometimes be
observed in the upper, foveolar layerofthe
gastric mucosa, without any signs ofa loss
of glands in the deeper glandular layer. In
addition, antral specimens obtained close
to the pylorus may normally contain
intestinal cells as the border between gas-
tric and intestinal tissue is not necessarily
located exactly in or distal of the pylorus.
In general, atrophic gastritis leads to
replacement with fibrous tissue, which,
therefore, is a marker for previous gland
loss.Additionally, ithas been argued that aKuipers et al.: H. pylori, PPIs, and GERD 215
loss of gastric glands does not reflect an
increased gastric cancer risk, as such an
increased cancer risk is confined to
patients with type III intestinal metaplasia.
This statement was based on a single
cohort study from Slovenia [24], in which
patients in whom intestinal metaplasia had
been diagnosed in the past, were re-stud-
ied after long-term follow-up. The authors
suggested that the development of cancer
was largely confined to patients with apre-
vious diagnosis of type III metaplasia,
which resembles colonic mucosa with
sulphomucins containing columnar cells
in distorted crypts. However, re-analysis
of the archival parafin-embedded gastric
specimens did not reveal any metaplasia at
all in a considerate proportion of patients
[24]. When one takes this into account, the
outcome of the study does not reveal any
relation between intestinal metaplasia sub-
types and gastric cancer. This outcome is
in agreement with another follow-up study
[25] and also explains why the large
majority ofpatients with gastric cancer do
not have any signs of type III intestinal
metaplasia. In summary, our definition of
atrophy is in accordance with the current
international criteria and represents a con-
dition with an increased cancer risk as it
sets the stage for development of further
(pre-) neoplastic changes. There is no con-
vincing evidence that such an increased
risk is confined to the small subcategory of
patients with type III intestinal metaplasia.
PPIs and H. pylori: interaction depen-
dent upon age and country oforigin?
We studied the incidence of atrophic
gastritis in GERD patients treated either
with omeprazole or with a fundoplication
and concluded that profound acid suppres-
sion in H. pylori-infected patients increas-
es the rate ofdevelopment ofatrophic gas-
tritis [1]. However, this was not a random-
ized study, but a comparison of two inde-
pendent cohorts. The fundoplication
patients were treated in Sweden and the
omeprazole patients in the Netherlands. In
addition, the mean age of the Swedes was
nine years lower (53 vs. 62 years). Could
our results have been induced by these dif-
ferences in age and country oforigin? It is
well known that atrophy is more common
among elderly (i.e., the prevalence ofatro-
phy). This has led to the assumption that
the rate of new development of atrophy is
also higher among elderly, i.e. the inci-
dence ofatrophy. There is, however, no lit-
erature evidence to support such conclu-
sion. Those studies that focused on the
incidence ofatrophy did not find a signifi-
cant relation with age [16-18]. Our study
focused on the incidence of atrophy and
found it more than three-fold increased in
H. pylori-positive subjects treated with
profound acid suppression. It is plausible
to explain this by the effect of acid sup-
pression on H. pylori and gastritis, where-
as it cannot be explained by the limited
age difference between our two cohorts.
Could it be that Dutch individuals have a
higher genetic risk for atrophic gastritis
and gastric cancer? It has been suggested
at an FDA meeting on this issue in
November 1996 that the gastric cancer
incidence is higher in the Netherlands
compared to Sweden. The reverse, howev-
er, is true. The gastric cancer incidence is
actually somewhat higher both for men
and women in Sweden [26]. There is,
therefore, no evidence that geographical
differences can explain our findings. In
addition, the available cohort studies on
the development of atrophic gastritis con-
sistently describe a low incidence of atro-
phy among subjects with a normal acid
production irrespective of their age. In
contrast, those studies performed during
profound acid suppression consistently
describe a high incidence of atrophy irre-
spective of the mean age.
Accelerated atrophy development
refuted by other data?
As pointed out in the previous para-
graphs, ourfindings were fully corroborat-
ed by other data. Recently, however, two
new studies have been presented that were
said to refute our findings and those of all216 Kuipers et al.: H. pylori, PPIs, and GERD
previous studies. Lundell and colleagues
from Sweden presented a randomized
study ofGERD patients treated with either
a fundoplication or omeprazole [27]. No
significant differences were observed
between both groups with respect to the
incidence ofatrophic gastritis during a fol-
low-up of three years. However, the inci-
dence of atrophic gastritis among the
omeprazole treated patients was high (4.2
percent annually). The incidence among
the fundoplication patients was lower (2.8
percent), but higher than the 1 to 2 percent
observed in previous Western studies in
populations with normal acid production
[14, 17]. The use of omeprazole pre- and
postoperatively, as well as inclusion of
patients with a previous vagotomy may
have been confounding factors leading to
this study result.
Unpublished data presented at an
FDA meeting on this issue (November
1996), described a one percent incidence
of atrophic gastritis among 99 H. pylori-
infected GERD patients treated with lan-
soprazole for 15 months. However, the
limited size and follow-up ofthis study led
to large confidence limit for the reported
incidence. More importantly, the investi-
gators performed a protocol by which his-
tological specimens were stepwise scored
by different pathologists in case of abnor-
malities. This policy is likely to have
induced a selection against the diagnosis
of atrophy. In another lansoprazole study,
the incidence of atrophy in H. pylori-
infected subjects was consistent with the
observations during omeprazole therapy
[28].
In summary, these data support the
hypothesis that reduction ofacid output by
pharmaceutical agents (or vagotomy)
induces an increase of corpus gastritis in
H. pylori -positive patients, which leads to
further reduction of acid output by accel-
erated development ofcorpus atrophy.
CONCLUSION
Proton pump inhibitors have become
of pivotal importance for the treatment of
GERD. Recent data have made us aware
that the effect and long-term outcome of
PPI treatment may depend on the H. pylori
status ofthe patient. During treatment with
PPIs, H. pylori-positive subjects have a
higher intragastric pH than H. pylori-neg-
ative subjects. The mechanism for this
phenomenon remains to be elucidated. It is
likely to be related to H. pylori-induced
corpus gastritis, which impairs parietal
cell function. The available evidence, how-
ever, suggests that this phenomenon has no
clinical relevance for the treatment of
GERD. The 24-hr esophageal pH during
PPI treatment does not depend on the H.
pylori status, nor does the medication dose
needed for maintenance therapy or the
number of clinical relapses during such
therapy. Therefore, a prescription of PPIs
for GERD does not have to take the H.
pylori status into account. PPIs, on the
other hand, also affect H. pylori. During
treatment with these drugs, the pattern of
bacterial colonization and associated gas-
tritis shifts proximally. The increased gas-
tritis ofthe body mucosais associated with
a more rapid development ofatrophic gas-
tritis, a condition characterized by a loss of
gastric glands and associated with an
increased cancer risk. For these reasons,
one has to consider H. pylori eradication
in infected GERD patients in need of PPI
maintenance therapy.
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